The success of Sildenafil initially drove a period of growth for pharma, nevertheless recent shifts present a uncertain scenario for investors. Off-patent alternatives are eating into profits, and persistent litigation https://hamzahgltb129130.eedblog.com/41459236/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet